Real-World Case Insight: Triple FDC Therapy in a Young Diabetes Patient - Dr Naresh Kumar
In this video, Dr. Naresh Kumar, Consultant Diabetologist from Tamil Nadu, presents a real-world case of a 24-year-old male student with fatigue and polyuria, diagnosed with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) risk.The patient was initiated on a triple fixed-dose combination (FDC) of vildagliptin, dapagliflozin, and metformin, leading to rapid and sustained clinical improvements. Within just 4 weeks, fasting and postprandial blood glucose levels were effectively controlled. Over 6 months, HbA1c dropped significantly from 9.3% to 6.5%, reflecting excellent glycemic management. Notably, homocysteine levels normalized, reducing cardiovascular risk, while the patient reported marked improvement in energy levels, overall well-being, and quality of life.This case underscores the value of early initiation of vildagliptin–dapagliflozin–metformin FDC in young patients with uncontrolled T2DM and elevated CV risk, highlighting its efficacy, safety, and potential to improve both metabolic and cardiovascular outcomes.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!